AI algorithms from NGS and digital pathology to increase clinical context on patients

Our algorithmic diagnostics sit on top of common diagnostic modalities of NGS, IHC, and H&E, powering researchers with new, AI-driven insights to support clinical care, whether in clinical decision making or trial eligibility.

Contact us

Our Solutions

Get additional molecular context

Leverage Tempus AI-driven algorithms—such as HRD, TO, or DPYD—to gain molecular dimensionality to answer challenging scientific questions on patient outcomes.

Learn more about our algorithms

Partner in developing your own algorithm

Collaborate with Tempus’ data scientists and computational biologists to develop unique algorithmic biomarkers, whether based on DNA, RNA, or digital pathology, to support potential trial eligibility or clinicians' management of individual patients.

Validate your own algorithm

Partner with Tempus to leverage our capabilities to launch and operate studies and validate algorithms with prospective patients.

Identify patients earlier in their treatment journey

Deploy digital pathology algorithms in the Tempus NAPA network of pathology labs to identify patients who might qualify for your clinical trial—based upon an H&E image—potentially accelerating enrollment.

Our differentiators

  • 100+

    petabytes of data, which represents 25 times the size of the Cancer Genome Atlas

  • 700K+

    records with matched clinical data linked with genomic information

  • 1M+

    records with imaging data

  • 350+

    direct data connections across over 1,850 healthcare institutions that order our products and services

  • 90%

    of the top 20 pharma oncology companies partner with Tempus

image description

Partnering with Tempus is investing in the future

We believe our AI solutions can guide researchers in understanding patients’ underlying biology, potentially leading to improved access to treatments, clinical trials, and care.